

Luigi Elio Adinolfi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1654709/publications.pdf>

Version: 2024-02-01

96
papers

5,649
citations

94269

37
h-index

79541

73
g-index

97
all docs

97
docs citations

97
times ranked

6009
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 26-34. | 1.0 | 10 |
| 2 | Early Lymphopenia and Infections in Nontraumatic Subarachnoid Hemorrhage Patients. <i>Journal of Neurosurgical Anesthesiology</i> , 2022, 34, 243-247. | 0.6 | 5 |
| 3 | Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O ₂ Therapy: A Prospective Controlled Nonrandomized Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e403-e409. | 2.9 | 40 |
| 4 | Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 0106. | 0.5 | 15 |
| 5 | Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. <i>Scientific Reports</i> , 2022, 12, 5771. | 1.6 | 7 |
| 6 | Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology?. <i>Biology</i> , 2022, 11, 609. | 1.3 | 7 |
| 7 | Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. <i>Frontiers in Immunology</i> , 2022, 13, 882064. | 2.2 | 7 |
| 8 | The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. <i>Clinical Oral Investigations</i> , 2022, 26, 5409-5417. | 1.4 | 6 |
| 9 | Circulating miRNA-195-5p and -451a in Patients with Acute Hemorrhagic Stroke in Emergency Department. <i>Life</i> , 2022, 12, 763. | 1.1 | 3 |
| 10 | Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. <i>Processes</i> , 2021, 9, 135. | 1.3 | 62 |
| 11 | Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 643-656. | 1.4 | 8 |
| 12 | Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. <i>Minerva Medica</i> , 2021, 112, 188-200. | 0.3 | 13 |
| 13 | Clinical impact of direct-acting antiviral treatment on patients with hepatitis C virus-related oral lichen planus. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, e113. | 0.2 | 1 |
| 14 | Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 256-263. | 1.0 | 2 |
| 15 | Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. <i>Cardiovascular Diabetology</i> , 2021, 20, 145. | 2.7 | 91 |
| 16 | Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2345-2353. | 1.1 | 40 |
| 17 | Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. <i>PLoS ONE</i> , 2021, 16, e0256903. | 1.1 | 8 |
| 18 | A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. <i>Viruses</i> , 2021, 13, 2249. | 1.5 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 517-519. | 2.4 | 12 |
| 20 | Relevance of lung ultrasound in the diagnostic algorithm of respiratory diseases in a real-life setting: A multicentre prospective study. <i>Respirology</i> , 2020, 25, 535-542. | 1.3 | 15 |
| 21 | Hepatitis B and C virus infection and risk of haematological malignancies. <i>Journal of Viral Hepatitis</i> , 2020, 27, 4-12. | 1.0 | 9 |
| 22 | Liver fibrosis by FibroScan [®] independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. <i>Liver International</i> , 2020, 40, 347-354. | 1.9 | 59 |
| 23 | Circulating MiRNA-195-5p and -451a in Diabetic Patients with Transient and Acute Ischemic Stroke in the Emergency Department. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7615. | 1.8 | 22 |
| 24 | NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107684. | 1.2 | 11 |
| 25 | Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. <i>JGH Open</i> , 2020, 4, 713-721. | 0.7 | 18 |
| 26 | Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2408-2416. | 2.2 | 58 |
| 27 | Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1806-1812. | 1.1 | 2 |
| 28 | The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-8. | 1.0 | 106 |
| 29 | Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. <i>Cancers</i> , 2020, 12, 1351. | 1.7 | 50 |
| 30 | Metformin: An old drug against old age and associated morbidities. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 108025. | 1.1 | 64 |
| 31 | Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020, 296, 40-47. | 0.4 | 78 |
| 32 | Atypical Presentation of a Rare Parasitic Infection with <i>Fasciola hepatica</i> : A Multidisciplinary Case Report. <i>American Journal of Case Reports</i> , 2020, 21, e924704. | 0.3 | 4 |
| 33 | Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. <i>PLoS ONE</i> , 2020, 15, e0243700. | 1.1 | 36 |
| 34 | Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. <i>Exploration of Medicine</i> , 2020, 1, . | 1.5 | 37 |
| 35 | Viral Hepatitis C. , 2020, , 181-195. | | 0 |
| 36 | Metformin lactic acidosis: Should we still be afraid?. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107879. | 1.1 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , 2019, 17, 292. | 1.8 | 49 |
| 38 | Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1274-1282. | 0.6 | 11 |
| 39 | Circulating MiRNA-195-5p and -451a in Transient and Acute Ischemic Stroke Patients in an Emergency Department. <i>Journal of Clinical Medicine</i> , 2019, 8, 130. | 1.0 | 19 |
| 40 | Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. <i>Cardiovascular Diabetology</i> , 2019, 18, 24. | 2.7 | 78 |
| 41 | High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study. <i>Diabetes Research and Clinical Practice</i> , 2019, 150, 236-244. | 1.1 | 35 |
| 42 | Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3013-3019. | 1.1 | 33 |
| 43 | AB0648â€¦CORRELATIONS BETWEEN NEUTROPHIL/LYMPHOCYTE RATIO AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , . | | 0 |
| 44 | Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018, 69, 18-24. | 1.8 | 98 |
| 45 | Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. <i>Infection</i> , 2018, 46, 231-238. | 2.3 | 13 |
| 46 | Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1123-1130. | 1.4 | 18 |
| 47 | Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1379-1382. | 1.4 | 64 |
| 48 | Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 143-146. | 0.7 | 5 |
| 49 | Expert Opinion on Managing Chronic HCV Infection in Patients with Type 2 Diabetes Mellitus. <i>Antiviral Therapy</i> , 2018, 23, 11-21. | 0.6 | 11 |
| 50 | Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-8. | 1.0 | 69 |
| 51 | Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?. <i>World Journal of Gastroenterology</i> , 2018, 24, 4617-4621. | 1.4 | 31 |
| 52 | Applicability of telemedicine in the screening of diabetic retinopathy (DR): The first multicentre study in Italy. The No Blind Study. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 35, e3113. | 1.7 | 55 |
| 53 | Uncommon immune-mediated extrahepatic manifestations of HCV infection. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 1089-1099. | 1.3 | 11 |
| 54 | Endotoxemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. <i>Infection</i> , 2018, 46, 793-799. | 2.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 595-597. | 2.0 | 13 |
| 56 | Sonoporation by microbubbles as gene therapy approach against liver cancer. <i>Oncotarget</i> , 2018, 9, 32182-32190. | 0.8 | 22 |
| 57 | The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. <i>Saudi Journal of Gastroenterology</i> , 2018, 24, 25. | 0.5 | 15 |
| 58 | No effect of MTP polymorphisms on PNPLA3 in HCV-correlated steatosis. <i>Infezioni in Medicina</i> , 2018, 26, 244-248. | 0.7 | 2 |
| 59 | Seasonal variations of hyponatremia in the emergency department: Age-related changes. <i>American Journal of Emergency Medicine</i> , 2017, 35, 749-752. | 0.7 | 33 |
| 60 | Chronic Hepatitis C Virus Infection and Depression. <i>Clinics in Liver Disease</i> , 2017, 21, 517-534. | 1.0 | 46 |
| 61 | Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 1458. | 1.4 | 38 |
| 62 | Nonalcoholic fatty liver disease: Evolving paradigms. <i>World Journal of Gastroenterology</i> , 2017, 23, 6571-6592. | 1.4 | 138 |
| 63 | NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. <i>International Journal of Molecular Sciences</i> , 2016, 17, 803. | 1.8 | 85 |
| 64 | Diseases associated with electrolyte imbalance in the ED: age-related differences. <i>American Journal of Emergency Medicine</i> , 2016, 34, 1923-1926. | 0.7 | 32 |
| 65 | CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. <i>Digestive and Liver Disease</i> , 2016, 48, 1364-1369. | 0.4 | 8 |
| 66 | Acute rhabdomyolysis in healthy woman. <i>American Journal of Emergency Medicine</i> , 2016, 34, 113.e1-113.e2. | 0.7 | 4 |
| 67 | Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. <i>World Journal of Hepatology</i> , 2016, 8, 949. | 0.8 | 5 |
| 68 | Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study. <i>Infezioni in Medicina</i> , 2016, 24, 278-286. | 0.7 | 1 |
| 69 | Hepatitis B virus burden in developing countries. <i>World Journal of Gastroenterology</i> , 2015, 21, 11941. | 1.4 | 220 |
| 70 | Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview. <i>World Journal of Gastroenterology</i> , 2015, 21, 2269. | 1.4 | 134 |
| 71 | Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3005-3010. | 1.1 | 10 |
| 72 | <sc>TM</sc>6<sc>SF</sc>2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of <sc>PNPLA</sc>3 polymorphism. <i>Liver International</i> , 2015, 35, 1959-1963. | 1.9 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. <i>World Journal of Hepatology</i> , 2015, 7, 2363. | 0.8 | 13 |
| 74 | Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment. <i>Infezioni in Medicina</i> , 2015, 23, 134-9. | 0.7 | 3 |
| 75 | Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant. <i>Infezioni in Medicina</i> , 2015, 23, 285-7. | 0.7 | 0 |
| 76 | Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. <i>World Journal of Gastroenterology</i> , 2014, 20, 3410. | 1.4 | 140 |
| 77 | PNPLA3 I148M variant as a risk factor for carotid atherosclerosis in chronic hepatitis C. <i>International Journal of Cardiology</i> , 2014, 172, 291-292. | 0.8 | 3 |
| 78 | Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 334-340. | 2.4 | 44 |
| 79 | Cannabinoid Receptor 2-63 QQ Variant Is Associated with Persistently Normal Aminotransferase Serum Levels in Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e99450. | 1.1 | 13 |
| 80 | Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. <i>World Journal of Hepatology</i> , 2014, 6, 677. | 0.8 | 14 |
| 81 | Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. <i>Infezioni in Medicina</i> , 2014, 22, 331-6. | 0.7 | 5 |
| 82 | Chronic HCV infection is a risk factor of ischemic stroke. <i>Atherosclerosis</i> , 2013, 231, 22-26. | 0.4 | 80 |
| 83 | The predictive value of steatosis in hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 205-213. | 1.4 | 26 |
| 84 | Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. <i>World Journal of Hepatology</i> , 2013, 5, 528. | 0.8 | 178 |
| 85 | Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. <i>Atherosclerosis</i> , 2012, 221, 496-502. | 0.4 | 164 |
| 86 | Metabolic alterations and chronic hepatitis C: treatment strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2215-2234. | 0.9 | 61 |
| 87 | Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 293-308. | 2.0 | 66 |
| 88 | Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. <i>Journal of Hepatology</i> , 2008, 48, 399-406. | 1.8 | 97 |
| 89 | Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. <i>Gastroenterology</i> , 2006, 130, 1636-1642. | 0.6 | 517 |
| 90 | Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. <i>Hepatology</i> , 2005, 41, 995-1003. | 3.6 | 113 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. <i>Gastroenterology</i> , 2004, 126, 586-597. | 0.6 | 433 |
| 92 | Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. <i>British Journal of Haematology</i> , 2001, 113, 590-595. | 1.2 | 161 |
| 93 | Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies. <i>Clinical Transplantation</i> , 2001, 15, 415-420. | 0.8 | 18 |
| 94 | Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1677-1683. | 1.1 | 88 |
| 95 | Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. <i>Hepatology</i> , 2001, 33, 1358-1364. | 3.6 | 922 |
| 96 | Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. <i>Hepatology</i> , 1999, 30, 1530-1531. | 3.6 | 39 |